ERBB2 and neoplasm: With regard to HER2 as a predictive factor, retrospective studies have suggested that the benefit from anthracycline-containing chemotherapy might be greater in women whose tumour overexpresses HER2 (Paik et al, 1998, 2000; Di Leo et al, 2002).